F077 Think Like an Expert about Ichthyosis
DESCRIPTION
This session will be a lively, highly interactive discussion of challenging ichthyosis patient cases and updates and controversies in the field. Audience members will have a unique opportunity to observe how complex cases are approached by experts in their daily practice, as well as interact with and ask questions of these experts. A patient advocate will be present to provide the patient perspective.
LEARNING OBJECTIVES
Develop an approach to managing patients with unfamiliar, uncommon, and complex skin disease.
Order appropriate genetic testing for patients with ichthyosis and other inherited skin conditions.
Locate educational and support resources for patients affected by ichthyosis and their families
SCHEDULE
9:00 AM
Introduction and agenda
Cheryl Marie Bayart, MD, FAAD
9:05 AM
New insights into epidermal differentiation disorders (EDDs)
Juliette Mazereeuw-Hautier
9:20 AM
New insights into epidermal differentiation disorder (EDD) pathogenesis from the Registry for Ichthyosis and Related Skin Types
Xingyuan Jiang
9:35 AM
The surprising spectrum of epidermal differentiation disorders (EDDs): case-based insights into rare subtypes
Maria-Angela Hernandez-Martin, MD, IFAAD
9:50 AM
The epidermal differentiation disorder (EDD) patients you are not seeing
Denise Gass
10:00 AM
Small molecule inhibitors, new biologics, and recombinant proteins for epidermal differentiation disorders (EDDs)
Amy S. Paller, MD, FAAD
10:15 AM
Practical tips for patients with palmoplantar epidermal differentiation disorders (pEDDs)
Janice Schwartz
10:25 AM
Therapeutic concept and landscape for painful palmoplantar epidermal differentiation disorders (pEDDs)
Joyce Teng, MD, FAAD
10:40 AM
The new epidermal differentiation disorder (EDD) classification as a catalyst for collaboration and research: defining the future agenda
Antoni Gostynski, MD, PhD, MSc, IFAAD
10:55 AM
Q & A
DIRECTOR
Cheryl Marie Bayart, MD, FAAD
SPEAKERS
Denise Gass
Antoni Gostynski, MD, PhD, MSc, IFAAD
Maria-Angela Hernandez-Martin, MD, IFAAD
Xingyuan Jiang
Juliette Mazereeuw-Hautier
Amy S. Paller, MD, FAAD
Janice Schwartz
Joyce Teng, MD, FAAD
DISCLOSURES
Cheryl Marie Bayart, MD, FAAD
No financial relationships exist with ineligible companies.
Denise Gass
No financial relationships exist with ineligible companies.
Antoni Gostynski, MD, PhD, MSc, IFAAD
AbbVie – Advisory Board(Honoraria); Almirall – Advisory Board(Honoraria); Boehringer Ingelheim – Advisory Board(Honoraria); La Roche-Posay – Other(Grants/Research Funding); Leo Foundation – Other(Grants/Research Funding); Leo Pharma – Advisory Board(Honoraria); Novo Nordisk A/S – Stockholder Public Company(Stock); Pfizer – Stockholder Public Company(Stock); Pfizer Inc. – Advisory Board(Honoraria); Sanofi – Advisory Board(Honoraria); UCB – Advisory Board(Honoraria), Stockholder Public Company(Stock);
Maria-Angela Hernandez-Martin, MD, IFAAD
No financial relationships exist with ineligible companies.
Xingyuan Jiang
No financial relationships exist with ineligible companies.
Juliette Mazereeuw-Hautier
No financial relationships exist with ineligible companies.
Amy S. Paller, MD, FAAD
AbbVie – Data Safety Monitoring Board(Honoraria), Investigator(Grants/Research Funding); Abeona Therapeutics – Data Safety Monitoring Board(Honoraria); Arcutis Biotherapeutics – Consultant (1099 relationship)(Honoraria); BioCryst Pharmaceuticals, Inc. – Consultant (1099 relationship)(Honoraria), Data Safety Monitoring Board(Honoraria); BioMendics, LLC – Investigator(Grants/Research Funding); Boehringer Ingelheim – Consultant(Honoraria); Castle Creek Pharmaceuticals – Consultant (1099 relationship)(Honoraria); Chiesi Farmaceutici – Consultant (1099 relationship)(Honoraria); Daiichi Sankyo – Data Safety Monitoring Board(Honoraria); Dermavant Sciences, Inc. – Investigator(Grants/Research Funding); Eli Lilly – Consultant (1099 relationship)(Honoraria), Investigator(Grants/Research Funding); Galderma – Data Safety Monitoring Board(Honoraria); Incyte Corporation – Investigator(Grants/Research Funding); Johnson & Johnson Innovative Medicine – Consultant (1099 relationship)(Honoraria), Investigator(Grants/Research Funding); Krystal Biotech, Inc – Consultant(Honoraria); L'Oréal France – Consultant (1099 relationship)(Honoraria); Leo Pharma Inc – Consultant(Honoraria); MoonLake Immunotherapeutics – Consultant (1099 relationship)(Honoraria); Pelthos Therapeutics – Consultant (1099 relationship)(Honoraria); Quoin Pharmaceuticals Ltd – Consultant (1099 relationship)(Honoraria); Regeneron – Consultant(Honoraria), Investigator(Grants/Research Funding); Sanofi Genzyme – Consultant(Honoraria); UCB – Investigator(Grants/Research Funding);
Janice Schwartz
No financial relationships exist with ineligible companies.
Joyce Teng, MD, FAAD
Abeona – Consultant(Fees); AFT Pharmaceuticals – Consultant(Fees); Amryt Pharma – Consultant(Fees); Eden Brand – Advisory Board(Fees); Novartis – Investigator(Grants/Research Funding); Palvella Therapeutics – Consultant(Fees);